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ORIGINAL RESEARCH
ARTICLE
New emerging roles of the novel hepatokine
SERPINB1 in type 2 diabetes mellitus: Crosstalk
with b-cell dysfunction and dyslipidemia
MOHAMED MOSTAFA KAMAL, AYA ADEL, GHADA HUSSEIN SAYED, SHADIA RAGAB, and
DINA HAMADA KASSEM
CAIRO, EGYPT

Diabetes mellitus (DM) is a devastating metabolic disease. Recently, the cross-talk
between insulin-secreting-β-cells and various organs has sparked much interest. SerpinB1 emerged as a novel hepatokine inducing β-cell proliferation. However, its role in
type-2-DM (T2DM) patients has not been adequately studied. This study was designed to
investigate its circulating levels in subjects with/without T2DM, and to study its association
with β-cell function, as well as various glycemic-control and lipid-profile parameters.
Anthropometric data and biochemical markers including fasting plasma glucose (FPG),
HbA1C % and lipid profile parameters were measured in 55 T2DM patients, as well as 30
healthy nondiabetic subjects. Serum serpinB1, insulin and C-peptide levels were measured by ELISA. The homeostasis model assessment of both β-cell function (HOMA2-β%)
and insulin resistance (HOMA-IR) were calculated. SerpinB1 levels were found to be
significantly lower in T2DM patients 0.7 (0.2-12.4) ng/mL, compared to nondiabetic subjects 1.2 (0.94-24) ng/mL, P < 0.001, regardless of glycemic control, obesity, or insulin
resistance. Additionally, serpinB1 levels were found to be positively associated with
C-peptide, HOMA2-β% in all subjects; and BMI only in non-DM subjects; while negatively
associated with FPG, HbA1C% and lipid-profile parameters. Higher serum serpinB1 levels
were found to be associated with lower susceptibility for T2DM. Conclusively, serpinB1 is
associated with various aspects of β-cell dysfunction, glycemic-control, and dyslipidemia with a possible role in β-cell compensation in obese nondiabetic subjects. The
results of the current study shed lights on potential novel roles of serpinB1 in T2DM besides
its action as an inducer for β-cell proliferation. (Translational Research 2021; 231:112)
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Abbreviations: BMI = body mass index; DM = Diabetes mellitus; ELISA = Enzyme-Linked ImmunoSorbent assay; FPG = fasting plasma glucose; GLM = general linear modeling; HDL-C = highdensity lipoprotein-cholesterol; HOMA2-b = homeostasis model assessment of b-cell function;
HOMA-IR = homeostasis model assessment of insulin resistance; LDL-C = Low density lipoprotein
cholesterol; TC = total cholesterol; TG = triglycerides; T2DM = Type 2 diabetes mellitus

AT A GLANCE COMMENTARY
Kamal M.M., et al.
Background
Type 2 diabetes mellitus (T2DM) is a devastating
metabolic disease. Recently, the cross-talk between
insulin-secreting-b-cells and various organs has
sparked much interest. SerpinB1 is a novel hepatokine reported to induce b-cell proliferation.
Translational Significance
In the current study, serpinB1 levels were found to be
significantly lower in T2DM patients compared to
healthy nondiabetic subjects. Additionally, serpinB1
was found to be significantly interrelated with b-cell
function indices, as well as glycemic control and dyslipidemia, with a possible role in b-cell compensation
in obese nondiabetic subjects. Conclusively, serpinB1
is a new potential player in T2DM pathogenesis.
Careful consideration for serpinB1 and its mechanisms of action will undoubtedly reveal potential
novel therapeutic targets for T2DM.

INTRODUCTION

Diabetes mellitus (DM) is a seriously growing epidemic
currently affecting about 463 million people, with expected
rise to 700 million worldwide by the year 2045.1 Type 2
DM (T2DM) is the most common type, and is characterized by various degrees of insulin resistance and b-cell
dysfunction.2 Despite the fact that mechanisms responsible
for T2DM are not fully elucidated, it is well known that
hyperglycemia in T2DM results from progressive loss of
insulin secretion by b-cells with underlying insulin resistance in the background. Thus, impaired b-cell function
and insufficient compensation of b-cell mass are characteristic pathological features for T2DM.3
Interestingly, the crosstalk between pancreatic
b-cells and various organs provides potential opportunities to improve b-cell function and/or mass.4,5 The
liver-derived proteins (hepatokines) and their role in
the regulation of b-cell function and mass have sparked
much interest over the past few years.6 These

hepatokines include fetuin-A, fibroblast growth factor
21 (FGF21),7 as well as angiopoietin-like protein
(ANGPTL-8).8 In fact, the notion that a hepatokine
could regulate b-cell function/mass was highlighted
when serum from liver insulin resistance animal model
(liver insulin receptor knockout [LIRKO] mice)
induced b-cell proliferation in cultured islets.9
Among these hepatokines, serpinB1 (also known as leukocyte-neutrophil-elastase inhibitor) has recently been
identified to induce b-cell proliferation and enhance b-cell
mass.10 How exactly serpinB1 mediates such actions is not
fully understood. However, serpinB1 has been previously
reported to inhibit the activity of several proteases such as
neutrophil elastase,11 and neutrophil elastase was found to
be associated with the degradation of insulin receptor substrate-1.12 Moreover, inhibition of neutrophil elastase has
been reported to improve insulin sensitivity and glucose
tolerance.13 Interestingly, serpinB1 belongs to the superfamily of serine protease inhibitors which are an expanding family of structurally related and functionally-diverse
proteins.14 Previously, visceral adipose tissue-derived serpin (vaspin) was also identified as an insulin sensitizing
adipokine,15 with possible role in putative compensatory
mechanisms to insulin resistance in T2DM.16,17
Nevertheless, circulating levels of serpinB1 and its
possible implication into b-cell dysfunction in
patients with diabetes has not been adequately studied. On one hand, a recent study found that plasma
serpinB1 levels are associated with insulin sensitivity rather than b-cell function in Caucasian and African American nondiabetic subjects.18 On the other
hand, El Ouaamari and his coworkers reported that
circulating serpinB1 was positively correlated with
insulin resistance and BMI in subjects at risk of
developing T2DM.10 Knowing the extra layer of
complexity in different ethnic populations,4 we
decided to investigate the serum levels of serpinB1
in Egyptian T2DM patients.
Accordingly, in the light of all the previous findings,
we sought to determine the circulating levels of serpinB1 in Egyptian T2DM patients compared to healthy
nondiabetic subjects, and to study the association
between serpinB1 and b-cell dysfunction as well as
other biochemical and anthropometric parameters. To
the best of our knowledge, the interrelation between
serpinB1 and b-cell dysfunction, and its association
with C-peptide in T2DM has not been elucidated
before conducting the current work.
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MATERIAL AND METHODS
Study population and anthropometric measurements.

This study was approved by the ethical committee of the
National institute of Diabetes and Endocrinology-General
Organization For Teaching Hospitals and Institutes
(NIDEGOTHI- IDE00203), and informed consent was
obtained from every subject before participating in the
study. The current study was done in accordance with the
recommendations and regulations suggested by the Declaration of Helsinki.19 This study is considered a retrospective case-control study. A total of 85 subjects were
enrolled in the study; 55 patients with T2DM and 30 nondiabetic subjects. The T2DM patients were generally not
suffering diabetic complications as will be stated later in
this section as exclusion criteria. The nondiabetic subjects
were healthy volunteers having fasting plasma glucose
(FPG) level lower than 110 mg/dL and no family history
of T2DM. Meanwhile, they are not suffering any health
problems and were not receiving any dietary supplements
or medications. The 55 patients with T2DM were
recruited from the outpatient clinic of the National Institute of Diabetes and Endocrinology (NIDE), Cairo, Egypt.
The clinical characteristics of all the study subjects,
as well as the treatment regimen of the enrolled
patients are summarized in Table I. Briefly, 21 patients
were receiving oral hypoglycemic agents (OHA)
(either sulfonylurea or metformin), 32 patients were
receiving insulin therapy, and 2 patients were receiving
sulfonylurea and insulin therapy. All the included subjects were not receiving any drugs for dyslipidemia. To
gain further insight into the possible variation of circulating serpinB1 levels with the glycemic control status,
the Non-DM subjects were divided based on their
HbA1C%, into subjects with increased risk for diabetes
(HbA1C% 5.7%), and those with lower risk (HbA1C%
˂5.7%) as described according to the American Diabetes Association (ADA).20 Moreover, T2DM patients
were further subdivided based on their HbA1C% levels;
7% as controlled (n = 18), while >7% as uncontrolled
(n = 37) T2DM patients as described before by the
ADA.21 In addition, both the Non-DM and T2DM
groups were classified into nonobese (BMI ˂30 kg/
m2), and obese (BMI 30 kg/m2). Furthermore, both
groups of the study were further stratified based on
HOMA-IR score using an arbitrary cut-off value of
HOMA-IR less than 3 as an indication of a lower
degree of insulin resistance, and more than 3 as an indication of a higher degree of insulin resistance.22 Exclusion criteria were; any patient suffering from type-1DM, renal or hepatic disease, acute or chronic inflammatory disease, thyroid dysfunction, ischemic cardiovascular disease, retinopathy, alcohol or drug abuse,
cancer, acute or chronic infections, any hematological
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disorder as well as subjects taking hormonal therapy. It
is noteworthy that before conducting the study, we carried out a priori power analysis using G power software, and got a preliminary indication for the
minimum suitable total sample size which would
enable us to detect a significant difference (If exists)
between the Non-DM and T2DM groups with a reasonable power (0.9). The total sample size suggested was
around 68 subjects, accordingly we proceeded with
sample collection. Furthermore, after collecting the
samples we performed a post-hoc test for the actually
enrolled subjects’ number, which revealed the power
of our study to be between 0.81 and 0.93 for various
investigations.
All the study subjects underwent careful physical
examination, detailed history and laboratory investigations. Anthropometric parameters measured included
BMI and waist to hip ratio. Body weight and standing
height were measured in light clothing without shoes.
The BMI was calculated as weight divided by squared
height (kg/m2). Waist and hip circumferences were
measured to the nearest 0.1 cm at the narrowest point
between the uppermost lateral border of the iliac crest
and the lowest rib, while the hips were measured at
their widest point.
Blood sampling. All the blood samples were drawn
after overnight fasting and before the patients received
any of their medications on that day with the last dose
at least 12 hours prior to blood sampling. The samples
were divided into three aliquots. The first aliquot of
blood was collected on vacutainer tubes containing
sodium fluoride for FPG assay. The second aliquot of
blood was collected on vacutainer tubes containing
sodium Ethylene diamine tetra-acetic acid (EDTA) for
HbA1C % assay. The third aliquot of blood was collected on plain vacutainer tubes for serum preparation
used for the assay of lipids profile, C-peptide and serpinB1 levels. Afterward, serum samples were divided
into aliquots and stored at 80˚C for subsequent
assays.
Laboratory analyses. FPG and serum biochemical
parameters including triglycerides (TG), total cholesterol
(TC), and high-density lipoprotein-cholesterol (HDL-C)
were measured using Spectrum Diagnostics, Egypt kits.
Low density lipoprotein cholesterol (LDL-C) level was
calculated by Friedewald’s formula.23 The HbA1C % was
measured in whole blood using ion-exchange high-performance liquid chromatography using the Bio-Rad D-10
system (Bio-Rad Laboratories, Hercules, Calif).
Serum C-peptide levels were determined using human
C-peptide ELISA kit (DRG, catalog No. EIA-1293, Germany) with a sensitivity of 0.06 ng/mL, detection range
(0.06-16 ng/mL), intra-assay precision (CV = 5.13%),
and interassay precision (CV = 8.38%). The homeostasis
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Table I. Clinical and laboratory characteristics of the studied groups
Parameter
N (F/M)
Age (y)
Diabetes duration (Y)
BMI (kg/m2)
Waist (cm)z
WHRz
FPG (mg/dL)z
TC (mg/dL)
LDL-C (mg/dL)
HDL-C (mg/dL)z
TG (mg/dL)z
LDL-C/HDL-C
TC/HDL-C
HbA1C (%)
C-peptide (ng/mL)z
HOMA2-b %z
Insulin (mIU/mL)z
HOMA-IRz
SerpinB1 (ng/mL)z
Type of treatment
(OHA/OHA + Insulin/Insulin)

Non-DM

T2DM

P1

P2
x

30 (23/7)
37.17 § 1.6
. . .. . ..
29.5 § 0.81
110 (43-148)
0.91 (0.8-1.22)
82.5 (68-109)
155 § 6.56
92.13 § 6.83
47.5 (36-59)
82.5 (21-179)
2.05 § 0.18
3.413 § 0.198
5.4 § 0.09
2.7 (0.9-6.3)
165 (66-411)
11.73 (6.3-40)
2.4 (1.28-7.62)
1.2 (0.94-24)

55 (29/26)
49.2 § 1.46
8.47 § 0.93
30.98 § 0.57
108 (67-133)
0.94 (0.71-1.13)
185 (120-416)
224 § 6.16
136.01 § 5.2
44 (21-83)
204 (62-377)
3.32 § 0.22
5.31 § 0.24
8.5 § 0.29
0.68 (0.6-1.89)
16 (4-46.9)
10.5 (3-38.6)
5.7 (1.2-23.7)
0.7 (0.2-12.4)

0.037
˂0.001*
. . .. . .
0.141*
0.261y
0.141y
˂0.001y
˂0.001*
˂0.001*
0.219y
˂0.001y
˂0.001*
˂0.001*
˂0.001*
˂0.001y
˂0.001y
0.541y
˂0.001y
˂0.001y

—

21/2/32

—

. . .. . ..
. . .. . ...

. . .. . ..
0.306
0.166
0.558
˂0.001
˂0.001
˂0.001
0.402
˂0.001
0.004
˂0.001
˂0.001
˂0.001
˂0.001
0.549
˂0.001
˂0.001

Abbreviations: BMI, body mass index; DM, diabetes mellitus; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HbA1C%,
glycosylated hemoglobin; HOMA2-b%, homeostasis model assessment b-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low density lipoprotein cholesterol; OHA, oral hypoglycemic agent; Sulfonylurea and/or Metformin; TC, total cholesterol; TG, triglycerides; WHR, waist to hip ratio;
Results are expressed as mean § S.E.M, or as median (min-max). P1 value for independent samples t-test or Mann-Whitney U test. P2 value
after adjustment for the covariates age and gender by GLM.
*
P-value for independent samples t test.
y
P-value for Mann-Whitney U test.
z
Log transformed for performing GLM.
x
P-value for x2 test.

model assessment of b-cell function (HOMA2-b%) was
calculated from fasting C-peptide (ng/mL) and FPG (mg/
dL) using an online HOMA2 calculator/algorithms.24
Serum insulin levels were determined using human Insulin ELISA Kit (DRG, catalog No. EIA-2935, Germany)
with a sensitivity of 1.76 mIU/mL, detection range (1.76100 mIU/mL), intra-assay precision (CV = 2.6%), and
interassay precision (CV = 2.9%). The homeostasis model
assessment of insulin resistance (HOMA-IR) index was
calculated from fasting insulin and glucose by the following equation: HOMA-IR = fasting insulin (mIU/mL) £
fasting glucose (mg/dL)/405.25 Serum serpinB1 levels
were determined using human SerpinB1/leukocyte elastase inhibitor ELISA kit (Bioassay Technology Laboratory, catalog No. E2231Hu, China), with a sensitivity of
0.049 ng/mL, detection range (0.1 -40 ng/mL), intra-assay
precision (CV ˂8%), and inter-assay precision (CV
˂10%). All ELISA procedures were done according to
the manufacturer’s instructions using Chromate microplate reader (Awareness technology).
Statistical analysis. Results are expressed as mean §
standard error of mean (S.E.M), or as median (minmax) depending on data distribution of various variables. Kolmogorov-Smirnov and Shapiro-Wilk tests

were done to evaluate the distribution of various variables. For comparison between 2 groups, independent
sample t test and Mann-Whitney U test were used
appropriately according to the data distribution. To
compare serpinB1 levels among more than 2 groups,
KruskalWallisDunn’s test was done using GraphPad Prism 8.2.1. The general linear modeling (GLM)
was used to adjust for potential confounders (eg, age,
gender, BMI, HOMA-IR or disease state). In addition,
linear regression analyses to study the association
between serpinB1 and various parameters, before and
after adjustment for the effects of other covariates
(namely; age, gender, and BMI) were done. Any
skewed data was logarithmically transformed before
performing GLM, or linear regression analyses.
Finally, odds ratio (ORs) and 95% confidence intervals
(CI) for assessing the likelihood of T2DM based on
serpinB1 levels were determined by binary logistic
regression model, using diabetes-state as dependentvariable and serpinB1 as covariate, in addition to
age, gender, and BMI to adjust for their possible
confounding effects. All statistical analyses were
performed using Windows-based SPSS statistical
package (SPSS version 17.0, SPSS Inc, Chicago,
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Ill), and P-values 0¢05 were considered to be statistically significant.

RESULTS
Clinical laboratory data and serum levels of serpinB1.

The clinical characteristics as well as the circulating
levels of serpinB1 and other biochemical and metabolic parameters are shown in Table I. FPG and
HbA1C% were elevated in T2DM as compared to NonDM group. Also, TG, TC, LDL-C, as well as risk ratios
TC/HDL-C and LDL-C/HDL-C were all significantly
elevated in T2DM patients compared to healthy NonDM subjects. Additionally, C-peptide and HOMA2b%, were found to be significantly lower in T2DM
patients compared to Non-DM subjects. Moreover,
insulin levels failed to show significant difference in
diabetic vs nondiabetic subjects, however, expectedly,
HOMA-IR showed significant elevation in diabetic
group as compared to nondiabetic patients.
Afterwards, we carried out further classification for
the study groups based on BMI; to stratify any effect of
obesity on b-cell function and serum serpinB1 levels.
Both the Non-DM and T2DM groups were classified
into nonobese (BMI ˂30 kg/m2), and obese (BMI 30
kg/m2). All the clinical and laboratory characteristics
of these sub-groups are presented in Table II. In both
nondiabetic and diabetic groups; C-peptide, HOMA2b%, insulin, HOMA-IR showed no significant difference in obese as compared to nonobese subjects.
Regarding serum levels of serpinB1, as shown in Fig 1,
A, serum levels were found to be significantly lower in
T2DM patients compared to Non-DM subjects at P <
0.001. Even after adjustment for the effect of confounding
factors age and gender, as shown in Table I, serpinB1
remained to be significantly different among the studied
groups, P < 0.001. Afterward, T2DM patients were further
classified into patients receiving insulin therapy, and
patients receiving only OHA, both groups were found to
be significantly different from Non-DM group regarding
the serpinB1 serum levels (0.67 [0.21-10.39] ng/mL, 0.73
[0.25-12.35] ng/mL, and 1.17 [0.94-24] ng/mL, respectively) at P < 0.001. However, serpinB1 levels did not significantly differ between patients receiving insulin therapy
and those who were receiving OHA, as shown in Fig 1, B.
Furthermore, we studied the effect of glycemic control
in both Non-DM and T2DM groups. When classifying
the Non-DM subjects based on HbA1C%, into those with
increased risk for diabetes (HbA1C% 5.7%), and those
with lower risk (HbA1C% ˂5.7%); serpin B1 levels did
not differ significantly between the 2 groups. Regarding
controlled and uncontrolled T2DM patients, based on
their HbA1C% levels; 7% as controlled while >7% as
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uncontrolled diabetes status,21 as shown in Fig 1, C, serpinB1 levels were found to be significantly lower in both
uncontrolled and controlled T2DM patients compared to
healthy Non-DM subjects. However, no significant difference was observed between serpinB1 levels in uncontrolled versus controlled DM state. It’s noteworthy that
the same results were obtained when we compared serpinB1 serum levels in controlled diabetic patients with
HbA1c% 7% to those with HbA1C% levels 9%, and
also when comparing both groups to nondiabetic subjects,
as shown in Supplementary Fig. 1 (A). This indicates that
serpinB1 serum levels are lower in T2DM patients as
compared to Non-DM subjects regardless their control
over hyperglycemia or the received treatment.
To gain more insight into the effect of obesity on serpinB1 levels, we stratified both groups into obese and
nonobese based on their BMI as shown in Table 2 and
Fig 1, D, serpinB1 levels were found to be significantly
higher in obese Non-DM subjects as compared to nonobese ones. However, such significant difference was
not shown between nonobese and obese T2DM
patients. On the other hand, the levels of serpinB1
were found to be significantly lower in nonobese
T2DM patients compared to their nonobese Non-DM
counterparts. Likewise, serpinB1 levels were also
found to be significantly lower in obese T2DM patients
compared to obese Non-DM subjects (Fig 1, D). This
indicates that obesity is affecting the levels of serpinB1
in Non-DM subjects rather than in T2DM ones.
In order to study the levels of serpinB1 in subjects
with different HOMA-IR scores, we stratified both
Non-DM and T2DM subjects into subgroups based on
the observed levels of the insulin resistance index
HOMA-IR. As shown in Fig. 1, E, we could not find a
significant difference between the serpinB1 levels in
the stratified subgroups, neither for the nondiabetics
(1.14 [0.94-24] and 1.29 [1.1-11.57] ng/mL, respectively, P = 0.3), nor for the T2DM patients [0.65 [0.281.67] and 0.77 [0.25-12.35] ng/ml, respectively, P =
0.972]. Additionally, we stratified all subjects of the
study based on the observed levels of the insulin resistance index HOMA-IR. Initially, we found significant
lower serpinB1 levels in subjects with HOMA-IR more
than 3 as compared to those with HOMA-IR less than
3 (Less than 3: 1.06 [0.28-24] and more than 3: 0.73
[0.21-12.35], P-value 0.013), however, this difference
was lost after adjusting with GLM for the disease state
(P-value 0.54) and also after adjustment for the disease
state together with the covariates age and gender (Pvalue 0.643), and after adjustment for the disease state
together with age, gender, and BMI (P-value 0.856) as
shown in Supplementary Fig. 1 (B)).
Furthermore, in order to study the effect of HOMA-IR
in enrolled subjects in the context of obesity, we further
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Table 2. Clinical and laboratory characteristics of obese and nonobese subgroups
Parameter

Non-DM
Nonobese

N (F/M)
Age (y)
Diabetes duration
(Y)
BMI (kg/m2)
Waist (cm)z
WHRz
FPG (mg/dL)z
TC (mg/dL)
LDL-C (mg/dL)
HDL-C (mg/dL)z
TG (mg/dL)z
LDL-C/HDL-C
TC/HDL-C
HbA1C (%)
C-peptide (ng/mL)z
HOMA2-b %c
Insulin (mIU/mL)z
HOMA-IRz
SerpinB1 (ng/mL)z
Type of treatment
(OHA/OHA +
Insulin/Insulin)

Obese

T2DM
P1

P2
x

15 (11/4)
33.7 § 1.9
——-

15 (12/3)
40.6 § 2.3
——-

0.666
0.03*
——-

26.2 § 0.85
105 (97-120)
0.94 (0.85-1.05)
82 (68-109)
157 § 10.4
95 § 11.3
44 (38-58)
74 (37-119)
2.2 § 0.32
3.5 § 0.34
5.4 § 0.13
2.4 (0.9-5.8)
167 (66-411)
12 (9-16.8)
2.4 (1.97-3.7)
1.27 § 0.07
———-

32.8 § 0.6
115 (43-148)
0.91 (0.8-1.22)
85 (70-96)
153 § 8.3
89.3 § 8.1
48 (36-59)
86 (21-179)
1.9 § 0.19
3.3 § 0.21
5.45 § 0.12
3 (1.1-6.3)
163 (100-312)
10.3 (6.3-40)
2.4 (1.28-7.62)
4.38 § 1.7
———

˂0.001*
0.06y
0.648y
0.603y
0.793*
0.683*
0.771y
0.534y
0.488*
0.573*
0.787*
0.158y
0.310y
0.245y
0.468y
0.724y
——-

Nonobese

Obese

——————-

24 (8/16)
47.4 § 2.6
11.3 § 1.5

31 (21/10)
50.6 § 1.6
6.3 § 1.0

˂0.001
0.66
0.538
0.995
0.918
0.838
0.565
0.938
0.561
0.595
0.316
0.22
0.291
0.60
0.569
0.021
——

27.1 § 0.44
97 (67-114)
0.92 (0.71-1.13)
182 (121-388)
217 § 10.2
139.8 § 8.3
42.5 (21-83)
167 (62-320)
3.6 § 0.3
5.4 § 0.34
8.6 § 0.47
0.67 (0.6-1.3)
16.9 (4-32.7)
8.3 (3.8-38.6)
5.3 (1.8-13.5)
0.99 § 0.2
8/1/15

34.02 § 0.46
112 (91-133)
0.94 (0.85-1.06)
199 (120-416)
229 § 7.6
133.1 § 6.7
46 (21-77)
227 (89-377)
3.1 § 0.3
5.2 § 0.35
8.4 § 0.37
0.75 (0.6-1.89)
15.8 (4.3-46.9)
14.4 (3-29.6)
6 (1.2-23.7)
1.47 § 0.49
13/1/17

P1

P2
x

0.011
0.299*
0.008*

˂0.001*
˂0.001y
0.734y
0.865y
0.357*
0.532*
0.156y
0.024y
0.299*
0.630*
0.742*
0.116y
0.671y
0.641y
0.553y
0.879y
——

——
——
——

˂0.001
˂0.001
0.233
0.915
0.866
0.326
0.351
0.205
0.371
0.622
0.751
0.077
0.496
0.289
0.25
0.341
——

Abbreviations: BMI, body mass index; DM, diabetes mellitus; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HbA1C%,
glycosylated hemoglobin; HOMA2-b%, homeostasis model assessment b-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low density lipoprotein cholesterol; OHA, oral hypoglycemic agent; Sulfonylurea and/or Metformin;TC, total cholesterol; TG, triglycerides; WHR, waist to hip ratio.
Results are expressed as mean § S.E.M, or as median (min-max). P1 is the P-value for independent samples t test or Mann-Whitney U test. P2 is
the P-value after adjustment for the covariates age and gender by GLM.
*
P-value for independent samples t test.
y
P-value for Mann-Whitney U test.
z
Log transformed for performing GLM.
x
P-value for x2 test.

stratified obese and non-obese either nondiabetic or diabetic groups according to their HOMA-IR score, however
we failed to find any significant difference among these
subgroups as shown in Supplementary Fig. 2
Association of serum serpinB1 with various anthropometric

Afterwards, to gain further
insight into the relationship between serpinB1 and b-cell
dysfunction, insulin resistance, as well as glycemic and
lipid profile parameters, we performed simple linear
regression analyses using serpinB1 as an independent variable, and each of C-peptide, HOMA2-b%, FPG, HbA1C%,
TC, TG, LDL-C or TC/HDL-C risk ratio as dependent variable. As shown in Fig 2, linear regression analyses
revealed significant associations between serpinB1 and
various investigated parameters. It’s noteworthy that even
after adjusting for the effects of potential confounding factors, namely; age, gender and BMI, nearly all the associations shown in Fig 2 remained statistically significant: Cpeptide (b = 0.396, P ˂ 0.0001, Fig 2, A), HOMA2-b%
(b = 0.34, P = 0.001, Fig 2, B), FPG (b = 0.256, P =
0.016, Fig. 2, C), HbA1C% (b = 0.3, P = 0.006, Fig 2,
and biochemical parameters.

D), TC (b = 0.252, P = 0.019, Fig 2, E), TG (b = 0.3,
P = 0.003, Fig 2, F), TC/HDL-C risk ratio (b = 0.205,
P = 0.063, Fig 2, G), and LDL-C (b = 0.159, P = 0.161,
Fig 2, H). We also performed simple linear regression analysis using HOMA-IR as an independent variable, and serpinB1 as dependent variable. However, serpinB1 showed
nonsignificant association with HOMA-IR (b = 0.037,
P = 0.737), even after adjustment for the covariates age,
gender, and BMI, we could not find any significant association (b = 0.075, P = 0.498).
It is noteworthy that when we investigated the association of serpinB1 with the previous identified variables,
however with further adjustment for HOMA-IR together
with age, gender and BMI, most of these associations
remained relatively significant as follows: C-peptide
(b = 0.377, P ˂ 0.0001, Fig 2, A), HOMA2-b% (b = 0.309,
P = 0.001, Fig 2, B), FPG (b = 0.221, P = 0.018, Fig 2,
C), HbA1C% (b = 0.272, P = 0.007, Fig 2, D), TC (b =
0.236, P = 0.025, Fig 2, E), TG (b = 0.277, P = 0.004,
Fig 2, F), TC/HDL-C risk ratio (b = 0.196, P = 0.076,
Fig 2, G), and LDL-C (b = 0.151, P = 0.185, Fig 2, H).
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Fig 1. Serum serpinB1 levels in the studied groups. A, SerpinB1 levels in T2DM patients (n = 55) compared to Non-DM subjects (n = 30). B, SerpinB1 levels in T2DM patients receiving insulin therapy (n = 34)
and those receiving only oral hypoglycemic agents (Sulfonylurea and/or metformin) (n = 21) compared to
Non-DM subjects (n = 30). C-E, Serum serpinB1 levels in stratified subgroups; according to (C) HbA1C%
levels: Non-DM subjects were classified into those with relatively high risk for diabetes (HbA1C% 5.7%,
n = 9), and those with lower risk (HbA1C% ˂5.7%, n = 21); T2DM patients were classified into controlled
(HbA1C% 7%, n = 18), and uncontrolled (HbA1C% ˃7%, n = 37) patients. D, BMI values: Non-DM subjects
were classified into nonobese (BMI ˂30 kg/m2, n = 15), and obese (BMI 30 kg/m2, n = 15) subjects; T2DM
patients were also classified into nonobese (n = 24) and obese (n = 31) subjects. E, HOMA-IR: Non-DM subjects were classified into HOMA-IR ˂3 (n = 22), and HOMA-IR ˃3 (n = 8) subjects; T2DM patients were also
classified into HOMA-IR ˂3 (n = 15), and HOMA-IR ˃3 (n = 40). The band represents the median, Mann-Whitney or KruskalWallisDunn’s test was done, shown P-values are after adjustment for the covariates age and
gender by GLM. *Significantly different at P ˂ 0.05; ** significantly different at P ˂ 0.01; NS, nonsignificant. c
Log transformed values were used for the GLM analysis

We also performed various regression analyses in
separate study groups, before and after adjustment
for the covariates; age, gender and BMI; data shown
in Supplementary Table 1. SerpinB1 was found to
be significantly associated with BMI in the NonDM subjects (b = 0.421, P = 0.021), even after
adjustment for age and gender, the statistical significance was maintained (b = 0.5, P = 0.01).
Moreover, to dissect the relations among serpinB1,
obesity and b-cell function, we performed a correlation
analysis of serpinB1 with each of C-peptide and
HOMA2-b% in nonobese and obese subjects either in
Non-DM or T2DM group. These analyses are shown in
Supplementary Table 2.
Association of serum serpinB1 with T2DM risk. To gain
further insight into the relationship between serpinB1
levels and the risk for T2DM. We carried out binary

logistic regression analysis to determine the OR and
determine how the serpinB1 levels could affect the
likelihood of diabetes. This was performed using the
diabetes-state (being with/without diabetes) as the
dependent variable, and serpinB1 levels as a covariate,
in addition to age, gender, and BMI (to adjust for their
confounding effects). It has been found that the higher
the serum levels of serpinB1, the less the likelihood to
be with diabetes; OR = 0.705, CI (0.541-0.92),
P = 0.01. In addition, we did a Receiver operating
characteristic (ROC) analysis for serpinB1 and the
diabetes state to test if lower values of serpinB1 can
predict diabetes (Supplementary Fig. 4). Interestingly,
the ROC curve showed a significant area under the
curve of 0.839 with 95% CI 0.752-0.926 which indicates the ability of serpinB1 to discriminate diabetic
from nondiabetic subjects.
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Fig 2. Linear regression analyses between serpinB1 as an independent variable and (A) C-peptide, (B)
HOMA2-b%, (C) FPG, (D) HbA1C%, (E) TC, (F) TG, (G) TC/HDL-C risk ratio, (H) LDL-C as dependent
variables. c Log transformed values were used. HOMA2-b%, homeostasis model assessment b-cell function;
FPG, fasting plasma glucose; HbA1C%, glycosylated hemoglobin; TC, total cholesterol; TG, triglycerides;
HDL-C, high density lipoprotein cholesterol; and LDL-C, low density lipoprotein cholesterol. Black triangles
refer to T2DM patients, and grey circles refer to nondiabetic subjects.

DISCUSSION

In the current study, we sought to determine the
serum levels of sepinB1, a novel hepatokine with
emerging implications to regulate b-cell proliferation,
in T2DM patients compared to nondiabetic subjects.
We also studied its association with various glycemic
control and lipid profile parameters. In addition, we
assessed the possibility of using this parameter as a
possible predictor of T2DM susceptibility. Interestingly, serpinB1 serum levels were found to be significantly lower in T2DM patients compared to subjects
without DM. Moreover, serum serpinB1 showed moderate association with all glycemic control and lipid
profile parameters. Furthermore, serpinB1 could independently predict the likelihood of T2DM development. These results portrayed serpinB1 as a prominent
novel marker of T2DM for both prediction and prognosis of T2DM patients.
Previously, El-Ouaamari et al reported higher levels
of serpinB1 in subjects with risk factors for T2DM.10
Although the exact molecular mechanisms are not fully
elucidated, yet it is well established that T2DM is
indeed a progressive metabolic disease characterized
by insulin resistance and hyperglycemia. During the
disease process, the insulin-secreting b-cells have the
ability to compensate for increased insulin demand
during prediabetes via enhanced secretion and/or
expanded b-cell mass.26 Evidence for such adaptation/
compensation has been reported in various conditions
associated with insulin resistance like pregnancy27 or
obesity.28 Nevertheless, when such compensation

mechanisms are impaired, hyperglycemia and T2DM
manifests.3,26
Given the findings of the current study and the previous observation of higher serpinB1 levels in subjects at
risk of T2DM, it’s tempting to speculate that serpinB1
can be interrelated with such compensatory mechanisms of b-cells. This explains its higher levels in early
stages during compensation/adaptation phases; like the
situation previously reported by El-Ouaamari et al.10,
and lower levels in advanced stages of T2DM compared to healthy subjects without DM; the situation
observed in the current study.
However, another study reported relatively higher
levels of serpinB1 in Japanese T2DM patients as compared to healthy control subjects.29 Such discrepancy
can be explained by difference in patient characteristics, treatment regimens as well as possible ethnic differences. In that study by Takebayashi et al., nearly all
of the enrolled patients were receiving different types
of oral hypoglycemic agents, namely; sulfonylurea,
metformin, pioglitazone, a-glucosidase inhibitor, and
none of the patients was receiving insulin therapy.
Moreover, more than half of the enrolled patients in
that study were also receiving statins (16/30 enrolled
patients). Interestingly, the same study showed that
there exists a tendency toward higher levels of serpinB1 in T2DM patients receiving statins compared to
those who were not treated with statins.29 On the other
hand, our study was done on Egyptian T2DM patients;
55 diabetic patients were enrolled, of these 32 patients
were receiving insulin therapy alone, 21 were on oral
hypoglycemic agent (sulfonylurea or metformin), and
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2 patients were receiving sulfonylurea and insulin therapy, and none of our enrolled patients was receiving
statins or any other drug for dyslipidemia. In addition,
the diabetic patients enrolled in the study done by
Takebayashi et al. showed relatively higher level of
HbA1C% (around 10.4%) compared to the T2DM
patients in the current study (around 8.5%). However,
both groups are considered uncontrolled diabetic
patients as per the ADA guidelines as described before.
Thus, the patients’ characteristics and drug regimen
are quite different. This difference together with the
ethnic difference of the populations used in both studies can well explain such discrepancy. Indeed, the findings of our current study, in addition to theirs, further
shed lights on the crucial need for future large scale
well-designed longitudinal clinical studies to better
elucidate the circulating levels of serpinB1 and its
putative role during the course of T2DM progression.
It is also noteworthy, regarding the serpinB1 serum
level in nondiabetic healthy subjects, there has also been
some sort of discrepancy between the few published
reports, with varying ranges of detection. For example, ElOuaamari et al. reported serpinB1 serum levels in nondiabetics to be around 12.8 § 1 ng/mL,10 Takebayashi et al.
reported those levels to be around 5.69 § 1.64 ng/mL in
nondiabetic healthy Japanese subjects,29 while Glicksman
et al. reported 2.14 § 3.95 ng/mL serum levels in nondiabetic Caucasian and African Americans,18 and finally we
hereby reported serum levels to be around 1.17 (0.94-24)
ng/mL in our nondiabetic group of Egyptians. Generally,
the available reports for serpinB1 serum levels in humans,
either for control healthy subjects, for diabetic patients or
even for patients with other diseases, are very scarce, and
still there is no consensus neither regarding the normal
expected serpinB1 levels, nor regarding how would it be
altered (increased or decreased) in various conditions.
Interestingly, in the current study serpinB1 levels
were found to be significantly positively associated
with b-cell function indices; namely C-peptide and
HOMA2-b% levels. As far as our knowledge, this is
the first study to correlate serpinB1 with b-cell function
markers. Originally, serpinB1 was identified as a novel
hepatokine secreted by the liver of insulin resistance
rodent model; LIRKO mice. It was highlighted as a
liver-derived protein secreted in response to insulin
resistance, to regulate/enhance b-cell proliferation, and
mice lacking serpinB1 showed attenuated capacity for
b-cell compensation in response to insulin resistance.10
Our results come in accordance with these previous
findings, since higher serum levels of serpinB1 are
associated with higher C-peptide levels and better
b-cell function indices. On the other hand, serpinB1
levels were found to be negatively associated with FPG
and HbA1C% levels.
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As serpinB1 levels were shown to be elevated in
LIRKO mouse, an insulin resistance model that manifests islet hyperplasia,10 we tried to explore the correlation of serpinB1 with HOMA-IR. Interestingly, we
found a tendency for a relatively positive association
of serpinB1 with HOMA-IR only in nondiabetic subjects. However, such tendency could not be observed
neither in the T2DM patients, nor in the pooled study
subjects, as shown in Supplementary Fig. 3. Furthermore, serpinB1 showed a significant positive association with BMI, and consequently obesity, in
nondiabetic subjects only, while lacking such association in patients with diabetes. Thus, keeping in mind
all the findings of the current study, it seems that obesity can affect serpinB1 only in nondiabetic subjects
rather than T2DM patients. This comes in accordance
with the previous finding by El-Ouaamari et al. in subjects with risk factor for T2DM.10 One speculation of
such observation is that during normal state; or even in
prediabetes state, obesity may induce the secretion of
serpinB1, given the positive association between BMI
and serpinB1, which acts as a trophic factor for b-cells
and can help b-cells to compensate the insulin resistance state usually associated with obesity. This scenario may not be applicable in T2DM patients who
have already gone beyond b-cell compensation as our
subjects. This can be also explained by assuming that
the more the compensatory mechanisms are disrupted/
impaired, the less serpinB1 would be secreted and the
more the diabetic milieu would be aggravated; manifested by higher FPG and HbA1C% levels.
This comes in accordance with the observed positive
association of serpinB1 and b-cell function indices,
besides the other finding in this study that higher serpinB1
levels decrease the likelihood of developing diabetes, that
is, whenever obesity can cause elevation of serpinB1, this
can induce a b-cell compensatory state and help to prevent development of diabetes. However, in diabetic
patients, lower serpinB1 levels may reflect loss of one of
the compensatory mechanisms of b-cells, causing development of frank diabetes, beside the definite loss of association between BMI and serpinB1 levels in these
patients. Of course, such speculations require further
investigations in healthy and prediabetes subjects to confirm such role at clinical settings.
Actually to gain further insights into the effect of
obesity on serpinB1 levels and the possible association
of this effect with b-cell function, we further stratified
both Non-DM and T2DM groups into nonobese and
obese subgroups as shown in Table 2. Although all
b-cell functions parameters have shown nonsignificant
difference in nonobese versus obese subjects in the 2
groups, however, serpinB1 showed a significant elevation in the obese subjects compared to nonobese ones,

10

Kamal et al

only in the nondiabetic subjects. Such observation
implies that obesity may use serpinB1 to maintain
b-cells secretion and function only in the nondiabetic
subjects. Given that serpinB1 can act as a trophic factor
for b-cells, this can support the putative role played by
serpinB1 as a compensatory mechanism for insulin
resistance associated with obesity. In fact, this can be
further supported by an interesting report showing that
in nondiabetic subjects, obesity is associated with a
modest expansion of b-cell mass, possibly amounting—according to the best available estimates—to
10%-30% for each 10 kg of weight increment.30 Of
course, further studies are required to better elucidate
the association between obesity and b-cell function.
On the other side of the story, when comparing
obese and nonobese T2DM patients, insulin and
HOMA-IR were elevated not reaching significant levels and also serpinB1 was slightly nonsignificantly elevated in obese subjects. One can assume that these
T2DM patients have already lost the compensatory
mechanism which may have been induced by serpinB1.
To gain more insight into this compensatory role, we
classified each of the Non-DM and T2DM groups into
obese and nonobese subgroups and studied the correlation of serpinB1 with C-peptide and HOMA2-b% in
each of these subgroups. This compensatory effect was
confirmed with the observed negative association of
serpinB1 with HOMA2-b%, reaching only significance
in nondiabetic nonobese subgroup as shown in supplementary Table 2 that is, as the b-cell function declines,
the serpinB1 levels are elevated. On the other hand,
this association turned to a positive, although nonsignificant, one in the nondiabetic obese patients. This can
imply that in the nonobese nondiabetics, there is no
need for such compensatory mechanism, so the higher/
better b-cell function, the lower serpinB1 levels. However, in their obese counterparts, the relation tends to
become positively associated, because there is a need
for such compensatory mechanisms, so the higher the
serpinB1 levels, the higher/better b-cell function (the
same observation in the pooled study subjects). As for
the T2DM subgroups, they have already gone beyond
such compensation role of serpinB1 on b-cells, so there
is a very modest association of serpinB1 with HOMA2b% or C-peptide. Additionally, this lack of significance
of such association in the obese nondiabetic subjects
can be due to the relatively small number of subjects in the subgroup. We tried to illustrate this serpinB1-mediated cross-talk between liver and b-cells
in normal, obese and diabetic states in Fig 3. As far
as our knowledge, the association of serpinB1 with
obesity is not fully elucidated and requires further
investigations in the context of DM and other diseases.
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Furthermore, serpinB1 levels showed significant
negative association with TG, TC, and TC/HDL-C risk
ratio, as well as a tendency toward a negative association with LDL-C. This observation sheds light on the
possible interplay between serpinB1 and lipid metabolism. Actually, our finding also comes in accordance
with the previously reported negative association of
serpinB1 with LDL-C, as well as the tendency toward
higher levels of serpinB1 in T2DM patients receiving
statins compared to those who were not treated with
statins.29 The exact molecular mechanisms for such
interplay are not elucidated. However, most recently
the inhibition of neutrophil elastases has been reported
to inhibit experimental atherosclerosis.31 Moreover,
previously, polymorph nuclear cells’ elastase was
reported to modify LDL particles affecting its uptake
by human monocyte-derived macrophages.32 In fact,
our findings in addition to these previous reports shed
lights on the possibility that serpinB1 could mediate
several additional beneficial effects besides enhancing
b-cell proliferation during functional b-cell mass compensation. This can prove beneficial for cardiovascular
complications in patients with diabetes. A notion that
require further elucidation in DM patients with cardiovascular complications and the mechanisms behind
that association if proven.
It is also important to point here that higher serpinB1
levels were found to be associated with less likelihood of
T2DM occurrence in the current study and based on
ROC analysis can classify diabetic from nondiabetic subjects. Taking in consideration, all the previous reports,
this perfectly makes sense. Assuming that serpinB1 is
interrelated with various homeostatic compensatory
mechanisms for insulin resistance, thus when such mechanisms are impaired and serpinB1 level decreases, the
risk of developing T2DM increases. Interestingly, lower
levels of vaspin (another protease inhibitor with insulinsensitizing effects) were also previously reported as a risk
factor for T2DM progression.33 Accordingly, it is tempting to speculate that other unknown players could be possibly interrelated with serpinB1 and vaspin in these
putative compensatory mechanisms for insulin resistance.
Also, further clinical studies to investigate serpinB1 in
liver disorders like nonalcoholic fatty liver disease or
nonalcoholic steatohepatitis would be of good value.
Especially that liver sepinB1 expression in hepatic insulin
resistance has been reported to be regulated by the transcription factor FOXO-1 in a cell non-autonomous manner; meaning that additional unknown factors and
molecular mechanisms could be also mediating the regulation of serpinB1 expression by hepatocytes.34
Actually, the current study was limited by the relatively small sample size, and the fact that some patients
were receiving insulin therapy which complicates the
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Fig 3. Summary for suggested interplay of serpinB1 with obesity and T2DM. SerpinB1 is associated with
obesity only in non-diabetic subjects, which may be one of the compensatory mechanisms for insulin resistance
associated with obesity, implying a potential role of serpinB1 as a part of b-cell compensatory mechanisms in
non-diabetic state. On the other hand, serpinB1 is significantly decreased in T2DM patients compared to nondiabetic subjects. SerpinB1 is associated with various metabolic parameters and key players in T2DM disease
process such as b-cell dysfunction and dyslipidemia.

proper assessment of insulin resistance. Moreover, we
also counted only on the fasting levels of glucose, insulin and C-peptide to measure HOMA-IR and HOMA2b% as surrogate markers to assess insulin resistance
and b-cell function, rather than the hyperinsulinemic
euglycemic clamp which is the gold standard for accurate assessment of insulin resistance.25,35 Nevertheless,
our findings shed lights on the role of serpinB1 in
T2DM and its interplay with various metabolic parameters and key players in the disease process such as
b-cell dysfunction and dyslipidemia. Thus, unlike what
has been thought before, inducing b-cell proliferation
and b-cell functional mass compensation might not be
the only beneficial action of serpinB1.

CONCLUSION

Lower circulating serpinB1 levels were observed in
T2DM patients compared to non-diabetic subjects.
Serum serpinB1 levels were found to be significantly
associated not only with blood glucose parameters, but
also with b-cell function indices like C-peptide and
HOMA2-b%. In addition, serpinB1 was found to be
associated with obesity only in nondiabetic subjects,
which may be one of the compensatory mechanisms for
insulin resistance associated with obesity. Collectively,
our results indicate a potential role of serpinB1 as a part
of b-cell compensatory mechanisms in non-diabetic
state. Furthermore, serpinB1 showed significant associations with various lipid profile parameters, highlighting
its possible interplay with lipid metabolism, as well as
homeostatic compensatory mechanisms for dyslipidemia. It would indeed be of good value to investigate the
role of serpinB1 through further longitudinal studies

involving impaired glucose tolerance, as well as type-1DM, and/or patients suffering various diabetic complications. Further, in-depth thorough molecular studies are
warranted to elucidate its putative mechanisms of action
in T2DM. Unraveling the molecular basis of the
reported crosstalk of serpinB1 with b-cell dysfunction
and dyslipidemia will unveil potential novel therapeutic
targets for T2DM.
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